Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07122700 · ClinicalTrials.gov registry record
Evaluation of Non-Invasive Tests for Metabolic Liver Disease
A clinical trial of Cirrhosis, Liver and Liver Fibrosis, sponsored by Foundation for the National Institutes of Health.
- Recruiting
- Registry status
- 400
- Enrollment target
- 4
- Study locations
NCT07122700: Recruiting study of Cirrhosis, Liver and Liver Fibrosis, sponsored by Foundation for the National Institutes of Health.
NCT07122700 is a study of Cirrhosis, Liver and Liver Fibrosis that is actively recruiting participants, run by Foundation for the National Institutes of Health. The registered enrollment target is 400 participants, above the 230-participant average among 34 other Cirrhosis, Liver trials with a reported enrollment target (74% higher). The trial reports 4 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07122700, a study of Cirrhosis, Liver and Liver Fibrosis, is actively recruiting participants, sponsored by Foundation for the National Institutes of Health.
- RECRUITING
- Registry status
- 400 participants
- Enrollment target
- 4
- Study locations
Study Summary
The Non-Invasive Biomarkers for Metabolic Liver Disease (NIMBLE) study is a comprehensive, multi-year collaborative effort to standardize, validate and advance the regulatory qualification of blood- and imaging-based biomarkers to diagnose and stage Metabolic dysfunction-associated steatohepatitis (MASH), previously known as nonalcoholic steatohepatitis (NASH). MASH is characterized by liver inflammation accompanied by simultaneous fat accumulation in the liver.
Primary Outcome
Evaluate the diagnostic performance of individual and combined biomarkers (e.g., NIS2+, ADAPT \[PRO-C3-based score\], MRI-AST (MAST) \[MRE + PDFF + AST\], FAST and Metabolomics-Advanced Steatohepatitis Fibrosis (MASEF) \[included in the OWLiver Test\]) for identifying at-risk MASH (MASH + MAS ≥4 + fibrosis stage ≥2).
Conditions Studied
Study Locations (4)
Texas
- First Surgical Hospital - Bellaire
- Endeavor Clinical Trials - San Antonio
Florida
- Clinical Pharmacology of Miami - Miami
Ohio
- Ohio Clinical Trials - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2025-05-13 |
| Est. Completion | 2026-07-31 |
What NCT07122700 shows while recruiting
NCT07122700 is an observational study that tracks outcomes without assigning an intervention. The registered 400 participants enrollment target is mid-sized for trials with a published cap, above the 230-participant average among 34 other Cirrhosis, Liver trials with a reported enrollment target (74% higher).
The record links to 8 conditions, with Cirrhosis, Liver appearing as the primary indexed condition, and to 0 interventions.
NCT07122700 reports a single indexed study location in Texas, Florida, Ohio.
Frequently Asked Questions
What is clinical trial NCT07122700 about?
NCT07122700 is a clinical study titled "Evaluation of Non-Invasive Tests for Metabolic Liver Disease". The Non-Invasive Biomarkers for Metabolic Liver Disease (NIMBLE) study is a comprehensive, multi-year collaborative effort to standardize, validate and advance the regulatory qualification of blood- and imaging-based biomarkers to diagnose and stage Metabolic dysfunction-associated steatohepatitis (...
What is the current status of trial NCT07122700?
This trial is currently recruiting. The enrollment target is 400 participants. The study started on 2025-05-13. Estimated completion is 2026-07-31.
What conditions does trial NCT07122700 study?
This clinical trial studies the following conditions: Cirrhosis, Liver, Liver Fibrosis, NASH, Liver Fat, Liver Steatoses.
Who is sponsoring clinical trial NCT07122700?
This trial is sponsored by Foundation for the National Institutes of Health, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07122700 being conducted?
This trial has 4 study locations across Florida, Ohio, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cirrhosis, Liver
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07122700's enrollment target sits among peer trials
400 7th of 34 higher than 27 of 34 other Cirrhosis, Liver trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cirrhosis, Liver trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Single and Multiple Dose Escalation of PHIN-214 in Child-Pugh A and B Liver Cirrhotics
RECRUITING · Phase 1
-
Comparison Between 2-dose Versus 3-dose Regimens of Heplisav B in Cirrhosis
RECRUITING · Phase 4
-
Measuring Patient Reported Needs in Outpatient Liver Disease Management
RECRUITING
-
Molecular Mechanism of Exercise in Cirrhosis
RECRUITING · NA
-
Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States
RECRUITING · Phase 2
-
Development of 4D Flow MRI for Risk Stratification of Variceal Bleeding in Cirrhosis
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01665326 · 400 participants
Determination of CRIM Status and Longitudinal Follow-up of Individuals With Pompe Disease
- NCT02108054 · 400 participants · NA
Behavioral and Functional Task Development, Implementation, and Testing
- NCT02216500 · 400 participants · NA
Ketogenic Therapy Effects on Electrical and Metabolic Abnormalities in Epilepsy
- NCT02250352 · 400 participants
Core Biopsies for Establishing a Breast Tumor Tissue Repository
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI